Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy. Issue 4 (May 2017)

• Record Type: Journal Article
• Authors: Ghisoli, Maurizio; Rutledge, McCarley; Stephens, Philip J.; Mennel, Robert; Barve, Minal; Manley, Meghan; Oliai, Bahram R.; Murphy, Kathleen M.; Manning, Luisa; Gutierrez, Belen; Rangadass, Priyanka; Walker, Ashli; Wang, Zhaohui; Rao, Donald; Adams, Ned; Wallraven, Gladice; Senzer, Neil; Nemunaitis, John
• Is Part Of: Journal of pediatric hematology/oncology. Volume 39:Issue 4(2017)
• Publication Date: 2017-05
• Subjects: Ewing sarcoma -- Vigil -- immunotherapy; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; 618.9215
• DOI: 10.1097/MPH.0000000000000822
• Languages: English
• ISSNs: 1077-4114

Abstract

Abstract : Ewing sarcoma is a highly resistant disease with a <10% chance of survival at 5 years after failure of frontline chemotherapy. This is a case report of an Ewing sarcoma patient with metastatic disease recurrence <2 years after standard chemotherapy/radiation who achieved a durable and sustained complete response after 2 series of treatments with Vigil ( GMCSF/bi-shRNA furin DNA autologous tumor immunotherapy) serially manufactured from first and second recurrences with ELISPOT assay correlation. Results support justification of further testing of Vigil with ELISPOT assay as a biomarker to assess level of immune response and correlation with disease control.